Drug Use Investigation for Cervarix®
NCT01187927 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1230
Last updated 2015-01-26
Summary
This post-marketing study was designed to assess safety and efficacy of Cervarix® vaccine in Japanese female subjects under conditions of actual use.
Conditions
- Infections, Papillomavirus
Interventions
- BIOLOGICAL
-
Cervarix®
Administered according to the prescribing information in the locally approved label by the authorities.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Eligibility
- Min Age
- 10 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-09-30
- Primary Completion
- 2014-01-31
- Completion
- 2014-01-31
More Related Trials
-
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
NCT00811798 ·Status: COMPLETED ·Phase: PHASE3
-
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
NCT00316693 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
NCT00485732 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
NCT00492544 ·Status: COMPLETED ·Phase: PHASE3
-
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
NCT00456807 ·Status: COMPLETED ·Phase: PHASE3
-
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
NCT00541970 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
NCT00294047 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)
NCT01277042 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
NCT00552279 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
NCT00799825 ·Status: COMPLETED ·Phase: PHASE3
-
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
NCT01249365 ·Status: COMPLETED ·Phase: PHASE3
-
The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years
NCT04022148 ·Status: UNKNOWN
-
Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women
NCT00689741 ·Status: COMPLETED ·Phase: PHASE2
-
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
NCT00196937 ·Status: COMPLETED ·Phase: PHASE3
-
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
NCT01153906 ·Status: COMPLETED
-
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
NCT00996125 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
NCT00652938 ·Status: COMPLETED ·Phase: PHASE3
-
Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)
NCT00478621 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
NCT00250276 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years
NCT00290277 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
NCT00947115 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
NCT03629886 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
NCT00534638 ·Status: COMPLETED ·Phase: PHASE4
-
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
NCT00546078 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
NCT00586339 ·Status: COMPLETED ·Phase: PHASE2